Alertgy
Alertgy is a Florida-based medical device company developing a non-invasive continuous glucose monitoring wristband using RF dielectric spectroscopy and proprietary DeepGluco™ AI. Pre-revenue and in clinical trials, it targets diabetics and pre-diabetics as a pain-free alternative to finger-prick glucometers.
- Company typePrivate
- Founded2016
- HeadquartersMelbourne, United States
- Headcount11–50
- GTM typeB2C
- OfferingHardware or Manufacturing
What Alertgy does
Alertgy Inc. is a Melbourne, Florida-based medical device company founded in 2016 that is developing a non-invasive continuous glucose monitor (NICGM) in the form factor of a wristband. The product combines a radio frequency dielectric spectroscopy sensor — adapted from military sensor R&D — with proprietary AI and machine learning algorithms marketed as DeepGluco™. The system is designed to measure blood glucose at the arterial level up to three times per minute, eliminating the finger-prick, interstitial lag, and recurring consumable costs associated with traditional glucometers and incumbent CGM patches. A companion Bluetooth mobile app provides real-time readouts, trend analytics, customizable alerts to patients/families/providers, and optional data sharing with healthcare professionals.
The company serves two primary segments: type 2 diabetics (the 422 million worldwide and 29 million in the US) and the 86 million Americans with pre-diabetes. A secondary channel targets healthcare providers and health systems managing diabetic populations through nutrition and exercise programs. The intended revenue model is a one-time hardware sale of the wristband — with no recurring consumables — augmented by potential enterprise/subscription arrangements with healthcare organizations. Pricing has not been publicly disclosed.
Alertgy remains pre-revenue and is currently in clinical trials, targeting FDA and CE Mark approvals to enable consumer availability. The company is led by CEO Mark Semler (appointed March 2023, with prior executive experience at Orthofix and ZIAN), founder Marc Rippen now serving as Chairman and Chief Innovation Officer, and board director Dr. John Burd (founder of DexCom). Capital to date has come from a $1.2M seed round (2018) and roughly $1.5M–$2M in non-dilutive prize/grant funding from competitions including DxPx Conference, Luminate NY, NASA iTech, and FAU, plus a $600K financing in December 2023.
Alertgy firmographics
Firmographics- Name
- Alertgy
- Legal name
- Alertgy Inc.
- Website
- https://alertgy.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Alertgy is a Florida-based medical device company developing a non-invasive continuous glucose monitoring wristband using RF dielectric spectroscopy and proprietary DeepGluco™ AI. Pre-revenue and in clinical trials, it targets diabetics and pre-diabetics as a pain-free alternative to finger-prick glucometers.
- Ownership category
- akta.pro rank
Alertgy industry classification
Industry- Product category
- Continuous Glucose Monitoring
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Continuous Glucose Monitoring (CGM) Systems (HLAHAHAA)
- akta.pro secondary industries
- Blood Glucose Monitoring (BGM) Meters & Test Strips (HLAHAHAG), Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration) (HLACAPAI), Blood Glucose Monitoring Devices (Consumer CGM & Smart Glucometers) (CRACAQAE)
Keywords
Where Alertgy is headquartered
LocationHeadquarters
- HQ city
- Melbourne
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Alertgy business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Supply Chain
Revenue model
- Hardware Device Sales: Sale of the Alertgy NICGM wristband device as the primary product. The company emphasizes cost-effectiveness, eliminating the need for ongoing purchases of lancets, alcohol wipes, and testing strips. The final form factor will be a modern smartwatch design.
- Healthcare Provider Partnerships: Potential revenue from integrated partnerships with healthcare organizations for managing diabetic populations through nutrition and exercise programs.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Pay-as-you-go | Device pricing - details pending |
Go-to-market motion3 records
Distribution channels2 records
Marketing channels6 records
Alertgy product offering
Product offeringCore offering
Alertgy develops the NICGM (Non-Invasive Continuous Glucose Monitor), a wearable wristband device that measures blood glucose levels in real-time up to 3 times per minute using patented radio frequency dielectric spectroscopy combined with proprietary DeepGluco® AI/ML algorithms. The device measures blood glucose at the arterial level, eliminating the interstitial lag that affects competing CGM products, and removes the need for finger pricks, needles, patches, or blood draws. A Bluetooth companion mobile app provides trend analysis, multi-parameter monitoring (glucose, heart rate, blood oxygen, body temperature), 12 months of on-device data storage, and customizable emergency alerts to patients, family members, or healthcare providers.
Product overview
Alertgy offers a unified non-invasive continuous glucose monitoring system centered on the NICGM wristband device. The core product combines the Alertgy NICGM hardware (a wristband with embedded DeepGluco® sensor technology) with a companion mobile app. DeepGluco® serves as the AI-powered analytics engine that processes sensor data and delivers real-time measurements. Together, these products provide diabetics and pre-diabetics with pain-free, on-demand blood glucose monitoring along with automated alerts and trend tracking.
Differentiator
Problem solved
Functional benefit
Products and services
- Alertgy NICGM (Non-Invasive Continuous Glucose Monitor) A wearable wristband device that provides real-time, non-invasive continuous blood glucose monitoring without needles or blood draws, measuring blood glucose levels up to 3 times per minute at the arterial level using patented radio frequency dielectric spectroscopy combined with proprietary DeepGluco® AI/ML algorithms. The waterproof, hypo-allergenic device is worn 24/7, pairs via Bluetooth with a companion mobile app, provides multi-parameter monitoring (glucose, heart rate, blood oxygen, body temperature), stores up to 12 months of on-device data, and includes a customizable alert system that can automatically notify patients, family members, or healthcare providers of dangerous glycemic events.
Quantifiable outcome
- Improved HbA1c levels with self-monitoring of blood glucose in Type 2 diabetic patients
- +2 more outcomes
Companies that use Alertgy
Customer profileSegments3 records
Ideal customer profiles3 records
Alertgy technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature5 records
Alertgy partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and minor.
- Florida Atlantic University (FAU)coreAlertgy partnered with Florida Atlantic University's Immunology and Virology Department to conduct a collaborative research study on the diagnostic capabilities of Alertgy's dielectric sensor technology for detecting COVID-19. The research explores expanding the use of the field-based dielectric analyzer to include detection and identification of viral particles, with the goal of delivering a portable in vitro dielectric analyzer along with a mask-based viral trap system.
- SEMI FlexTechcoreAlertgy was awarded a Developer Agreement with SEMI FlexTech to develop a Flexible Hybrid Electronic Wristband Sensor Platform for non-invasive blood glucose monitoring along with other sensing functionality for military and civilian applications. SEMI is the global industry association representing the electronics manufacturing supply chain, connecting over 2,000 member companies and 1.3 million professionals worldwide. FlexTech is SEMI's Technology Community focused on the growth and success of flexible and printed electronics.
- NASA and Economic Development Commission of Florida's Space Coast (EDC)minorAlertgy was selected as one of the top 5 companies to participate in NASA and EDC's joint Technology Docking program, which connects innovative companies with resources for business development and growth on the Space Coast. The program advances opportunities and innovation through new business ventures.
Scale indicators6 records
Recent moves8 records
Expansion highlights6 records
Alertgy competitors and assessment
Company assessmentBroad incumbents
- DexCom: DexCom is the leading continuous glucose monitor (CGM) company with the G6 and G7 systems used by millions of diabetics. Alertgy's NICGM targets the same patient population with a non-invasive alternative; Alertgy's board includes DexCom founder Dr. John Burd.
- Abbott Diabetes Care: Abbott's FreeStyle Libre series is the highest-volume CGM globally and a direct competitor to Alertgy's NICGM wristband form factor and consumer-friendly positioning. Both target Type 2 diabetics and pre-diabetics seeking convenient glucose monitoring.
- Medtronic Diabetes: Medtronic's Guardian CGM system and MiniMed insulin pumps dominate the integrated diabetes management market. Alertgy's Senior Advisor previously held senior leadership roles within Medtronic's Restorative Therapies Group.
- Roche Diabetes Care: Roche's Accu-Chek line is one of the most widely used traditional blood glucose monitors globally. Alertgy's value proposition explicitly targets replacing finger-prick BGM with non-invasive monitoring, positioning Roche as a competitor in the same end-user workflow.
- Ascensia Diabetes Care: Ascensia markets the CONTOUR blood glucose monitoring portfolio, including the Eversense implantable CGM through partnership with Senseonics. As a traditional BGM incumbent with growing CGM exposure, Ascensia is comparable to Alertgy in target customer base.
Direct peers
- Senseonics: Senseonics developed the Eversense implantable CGM, pursuing long-term continuous glucose monitoring via a subcutaneous sensor. As a small-cap public medtech focused on novel CGM approaches, Senseonics is closely comparable in mission and stage to Alertgy.
- Know Labs: Know Labs is developing Bio-RFID, a non-invasive glucose monitoring technology using radio frequency spectroscopy, closely analogous to Alertgy's RF dielectric spectroscopy approach. Both target the same unmet need for needle-free glucose monitoring.
Emerging players
- Hagar (formerly Integrity Applications): Hagar's GlucoTrack product is a non-invasive glucose monitor using a combination of ultrasonic, electromagnetic, and thermal technologies. As a direct non-invasive CGM competitor pursuing regulatory clearance, Hagar is highly comparable to Alertgy's NICGM.
- LifePlus: LifePlus is developing a non-invasive continuous glucose monitoring wearable using multi-sensor technology. As an early-stage company pursuing non-invasive CGM via a wearable form factor, it is a direct emerging competitor to Alertgy's NICGM.
Others
- Apple: Apple has reportedly been developing non-invasive blood glucose monitoring for Apple Watch. While not yet a commercial product, Apple represents a potential adjacent entrant into the non-invasive CGM wearable space that Alertgy is pursuing.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Alertgy social profiles
Digital presenceAlertgy financial estimates
Financial estimateRevenue estimate
Valuation estimate
Alertgy leadership team
Management profileNumber of profiles
Profiles11 records
Alertgy funding detail
Funding detailFunding overview
Funding rounds4 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Alertgy M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Alertgy
What does Alertgy do?
Alertgy develops the NICGM (Non-Invasive Continuous Glucose Monitor), a wearable wristband device that measures blood glucose levels in real-time up to 3 times per minute using patented radio frequency dielectric spectroscopy combined with proprietary DeepGluco® AI/ML algorithms. The device measures blood glucose at the arterial level, eliminating the interstitial lag that affects competing CGM products, and removes the need for finger pricks, needles, patches, or blood draws. A Bluetooth companion mobile app provides trend analysis, multi-parameter monitoring (glucose, heart rate, blood oxygen, body temperature), 12 months of on-device data storage, and customizable emergency alerts to patients, family members, or healthcare providers.
Is Alertgy a public or private company?
Alertgy is a private company. It is classified as venture growth investor backed and is currently operating.
When was Alertgy founded?
Alertgy was founded in 2016. It employs 11 to 50 people.
Where is Alertgy based?
Alertgy is headquartered in Melbourne, United States, in the North America region.
How does Alertgy make money?
Two revenue lines are on record. Hardware Device Sales are the primary driver. The others are healthcare Provider Partnerships.
Who are Alertgy's main competitors?
Broad incumbents on record are DexCom, Abbott Diabetes Care, Medtronic Diabetes, Roche Diabetes Care and Ascensia Diabetes Care. Direct peers are Senseonics and Know Labs. Emerging players are Hagar (formerly Integrity Applications) and LifePlus. Apple is listed as an others.
Does Alertgy have an API?
No public API is recorded for Alertgy.
What industry is Alertgy in?
Alertgy's product category is Continuous Glucose Monitoring. Its primary akta.pro industry code is HLAHAHAA, Continuous Glucose Monitoring (CGM) Systems, with a secondary code of HLAHAHAG, Blood Glucose Monitoring (BGM) Meters & Test Strips. Its NAICS code is 334510 and its SIC code is 3841.